FACIT-Fatigue scores
Parameter . | Study 201, mean (SD) . | Study 103, mean (SD) . | ||||
---|---|---|---|---|---|---|
Cohort 1: . | Cohort 2: . | Cohort 3: . | Cohort 4: . | Cohort 1: . | Cohort 2: . | |
1000 mg q4w, . | 1600 mg q6w, . | 2400 mg q8w, . | 5400 mg q12w, . | 900 mg q4w, . | 1800 mg q4w, . | |
n = 6 . | n = 6 . | n = 7 . | n = 7 . | n = 6 . | n = 7 . | |
Baseline | 32.0 (11.02)* | 29.7 (17.32) | 28.7 (15.20) | 34.4 (10.08) | 35.5 (10.03) | 25.4 (14.35) |
End point† | 42.0 (6.45) | 39.4 (13.48)* | 40.8 (10.19)‡ | 43.3 (5.57)‡ | 41.8 (8.77) | 39.3 (10.48) |
Absolute change from baseline | 9.8 (8.70)* | 13.6 (11.01)* | 12.3 (16.87)‡ | 11.2 (8.64)‡ | 6.3 (11.38) | 13.9 (10.42) |
Parameter . | Study 201, mean (SD) . | Study 103, mean (SD) . | ||||
---|---|---|---|---|---|---|
Cohort 1: . | Cohort 2: . | Cohort 3: . | Cohort 4: . | Cohort 1: . | Cohort 2: . | |
1000 mg q4w, . | 1600 mg q6w, . | 2400 mg q8w, . | 5400 mg q12w, . | 900 mg q4w, . | 1800 mg q4w, . | |
n = 6 . | n = 6 . | n = 7 . | n = 7 . | n = 6 . | n = 7 . | |
Baseline | 32.0 (11.02)* | 29.7 (17.32) | 28.7 (15.20) | 34.4 (10.08) | 35.5 (10.03) | 25.4 (14.35) |
End point† | 42.0 (6.45) | 39.4 (13.48)* | 40.8 (10.19)‡ | 43.3 (5.57)‡ | 41.8 (8.77) | 39.3 (10.48) |
Absolute change from baseline | 9.8 (8.70)* | 13.6 (11.01)* | 12.3 (16.87)‡ | 11.2 (8.64)‡ | 6.3 (11.38) | 13.9 (10.42) |